- Editor's PickNicole Sinclair•yesterday
On Monday, Medivation (MDVN), which owns Xtandi, confirmed it was being acquired by Pfizer (PFE) for $14 billion. This comes just months after Sanofi (SNY) approached Medivation in a hostile deal, going public with its offer and beginning a process to replace the company’s board. Sanofi lost out on its bid to Pfizer, which was willing to pay up and fold Medivation into its oncology franchise.
- Editor's PickKathy Cherpelis•yesterday
Medivation (MDVN) stock surged this morning. The cancer drug maker is being bought by Pfizer (PFE) in a deal valued at about $14 billion. The deal is expected to close by the end of the year and will give Pfizer access to Medivation’s cancer drug pipeline.
- Editor's PickYahoo Finance•2 days ago
Stocks were mostly lower (^DJI, ^GSPC, ^IXIC) in early trading as investors remain cautious ahead of Federal Reserve Chair Janet Yellen’s speech at an annual symposium at Jackson Hole, Wyoming, later this week. The cancer drug maker is being bought by Pfizer (PFE) in a deal valued at about $14 billion. The deal is expected to close by the end of the year and will give Pfizer access to Medivation’s cancer drug pipeline.
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||35.02 x 300|
|Ask||35.26 x 1000|
|Day's Range||34.91 - 35.27|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||31.11|
|Avg Vol (3m)||22,355,103|
|Dividend & Yield||1.20 (3.43%)|